Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Alzheimer's Disease Clinical Trials

A listing of Alzheimer's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (43) clinical trials

Patient Inclusion Criteria: Ages: over 55-90 Male/Female 12 Month Long Clinical Trial MMSE score 24-30/20-26 Subjects must meet criteria for Prodromal AD or Mild AD: Mini Mental State Examination (MMSE) score between 20-30 Clinical Dementia Rating Scale (CDR) score of 0.5 or 1 a free recall score of lesser or ...


If you qualify, the study may involve 4 in-clinic stays,2 outpatient visits, and 1 telephone follow up. The in-clinic stays will consist of 3 days and 2 nights. You do not need medical insurance to participate in this research study.


If you qualify, the study may involve 3 screening visits, 1 separate in-clinic stay of 5 days/4 nights and 10 outpatient visits. All study exams and procedures are provided at no cost to you. You do not need medical insurance to participate.


This study will evaluate the safety and efficacy of NPT088 or Placebo in participants with probable Alzheimer's Disease


Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients With Alzheimer's Disease

This is a randomized, placebo-controlled clinical trial designed to evaluate the safety and efficacy of LMSCs (Longeveron Mesenchymal Stem Cells) or placebo in subjects with Alzheimer's Disease. Following a successful Safety Run-In Phase, a total of twenty-five (25) subjects will be randomized to (2:2:1) to receive low-dose LMSCs, high-dose LMSCs ...


[11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001)

The purpose of this open-label, 3-part study is to investigate the safety and efficacy of [11C]MK-6884 as a Positron Emission Tomography (PET) imaging agent for quantifying muscarinic 4 (M4) positive allosteric modulator (PAM) receptor density in brain regions of interest. The study will enroll healthy participants (Parts I and II) ...


A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD

The study will evaluate the effect of LY3002813 on brain scans. The study will evaluate the safety of LY3002813 by looking at adverse events (side effects). The study will also look at the effect the body has on LY3002813. Study participants will have mild cognitive impairment (MCI) due to AD ...


Aftobetin-HCl and Fluorescence Detection Measured by Sapphire II to Determine the Number and Timing of Administrations

Open label study. 45-105 subjects will be enrolled. Subjects will undergo the following procedures: Complete physical and neurologic examination (Screening) Neuropsychological testing (Screening) Ophthalmologic examination (Screening and Visit 4 (Safety follow up visit)) Administration of ointment - 3 administrations (Visit 1) Sapphire II Fluorescent Eye Measurements (Visits 1-3): Prior to ...


A Phase 1 Corplex Donepezil Trans-dermal System Compared to Oral Aricept

60 male and female subjects will be enrolled Subjects will receive 2 versions of once-weekly Corplex Donepezil TDS and QD oral Aricept; each administered for 35 days in 3 different treatment periods. For each treatment period; Subjects will receive a lead-in dose of approximately 5 mg donepezil/day for 7 days ...